Does Knowledge of Treatment Assignment Affect Patient Report of Symptoms, Function, and Health Status? An Evaluation Using Multiple Myeloma Trials-Reference-Cited by-同舟云学术

Does Knowledge of Treatment Assignment Affect Patient Report of Symptoms, Function, and Health Status? An Evaluation Using Multiple Myeloma Trials

Published:2021-06 Issue:6 Volume:24 Page:822-829
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

Roydhouse Jessica K.,Mishra-Kalyani Pallavi S.,Bhatnagar Vishal,Gutman Roee,King-Kallimanis Bellinda L.,Sridhara Rajeshwari,Kluetz Paul G.

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference42 articles.

1. The landscape and lexicon of blinding in randomized trials;Schulz;Ann Intern Med,2002

2. Blinding in randomised trials: hiding who got what;Schulz;Lancet,2002

3. Bias due to lack of patient blinding in clinical trials. A systematic review of trials randomizing patients to blind and nonblind sub-studies;Hrobjartsson;Int J Epidemiol,2014

4. Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: a network meta-analysis with the adjustment for the possible bias from open label studies;Morimoto;J Cardiol,2015

5. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study;Wood;BMJ,2008

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma;Journal of Clinical Oncology;2024-08-10

3. Pooled analysis of NeoCARH and NeoCART trials: patient-reported outcomes in patients with early-stage breast cancer receiving platinum-based or anthracycline-based neoadjuvant chemotherapy;Supportive Care in Cancer;2024-06

4. Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS);HemaSphere;2024-05

5. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial;The Lancet Oncology;2024-05